NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG TA357

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG TA357

1.1Pembrolizumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma in adults only:

  • after the disease has progressed with ipilimumab and, for BRAF V600 mutation‑positive disease, a BRAF or MEK inhibitor and

  • when the company provides pembrolizumab with the discount agreed in the patient access scheme

http://www.nice.org.uk/guidance/ta357 

Site by Devopa
© Copyright 2019 NHS. All rights reserved.